We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





15-minute COVID-19 Test Enables Highly Sensitive PCR Testing at POC Outside Laboratory Environment

By LabMedica International staff writers
Posted on 26 Apr 2021
Print article
Image: A nasal swab being processed by DASH at a sample collection site (Photo courtesy of Business Wire)
Image: A nasal swab being processed by DASH at a sample collection site (Photo courtesy of Business Wire)
A new SARS-CoV-2 test allows highly sensitive PCR testing to take place at the point-of-care and outside the traditional laboratory environment.

Minute Molecular Diagnostics, Inc. (Evanston, IL, USA) has been awarded a USD 21.3 million contract from the U.S. National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative for the company’s DASH (Diagnostic Analyzer for Specific Hybridization) point-of-care PCR system for COVID-19 testing. The contract supports further development of Minute Molecular’s DASH SARS-CoV-2 test.

The DASH system is the result of collaboration between Northwestern University’s Center for Innovation in Global Health Technologies (CIGHT) and Minute Molecular. The DASH system is an innovative point-of-care PCR testing system that is able to provide central lab precision in approximately 15 minutes. The DASH platform is adaptable to other infectious viral and bacterial agents (Flu A/B, RSV, HIV, STDs, MRSA, Cdiff.), sample types (nasal swab, saliva, whole blood, etc.), and can also quantitatively report a viral load (HIV). The RADx Tech contract will enable the development and manufacturing scale up of a highly sensitive COVID-19 detection system.

“We are pleased to receive support from NIH through the RADx initiative to scale our innovative technology during this critical time of need,” said Dr. David Kelso, co-founder, President, and CEO of Minute Molecular Diagnostics. “DASH performs point-of-care PCR testing for COVID-19 in approximately 15 minutes, providing an important, new tool for safely re-opening K-12 schools, universities, and workplaces.”

“DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes,” said Dr. Sally McFall, co-founder and Chief Scientific Officer at Minute Molecular. “The simplicity of the DASH test allows PCR testing to go where antigen tests go now.”

Related Links:
Minute Molecular Diagnostics, Inc.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.